Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for subl… Read more
Aspire BioPharma, Inc. (ASBP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.096x
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of 0.096x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($-11.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aspire BioPharma, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern Resources Ltd
AU:EFE
|
-0.010x |
|
AEMLF
PINK:AEMLF
|
N/A |
|
GECI International SA
PA:ALGEC
|
-0.006x |
|
CARLSON INV. ZY 13
F:2HB
|
N/A |
|
Marvion Inc.
PINK:MVNC
|
0.006x |
|
CHENIERE ENERGY
MU:CHQ1
|
0.149x |
|
MAV Beauty Brands Inc
PINK:MAVBF
|
-0.100x |
|
Kobexindo Tractors Tbk
JK:KOBX
|
0.622x |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -584.45% |
| 2022-12-31 | $289.07 Million | $-1.41 Million | -0.005x | -100.89% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |